tirzepatide research labs – Pure Compounding TIRZEPATIDE – Research Peptide |

The decision to wean or stop abruptly should be individualized based on several factors: Reason for discontinuation : Side effects, cost, achievement of weight goals, or medical contraindications Duration of treatment : Longer treatment periods may benefit from gradual transition Weight loss achieved : Greater weight loss may require more structured discontinuation planning Presence of comorbidities : Diabetes or cardiovascular conditions may need closer monitoring Patient preference and psychological readiness : Some individuals prefer gradual adjustment While not medically necessary, a stepwise reduction over 4-8 weeks allows patients to implement behavioral strategies, adjust dietary habits, and psychologically prepare for the metabolic changes that follow discontinuation

GLP-1 receptor agonists (GLP-1 RAs) are a class of medications that mimic a hormone your gut naturally releases after eating

Ge, S., Liu, W., Schlappi, T

GLP-1-based therapies carry recognised class-effect risks including pancreatitis, gallbladder disease, and gastrointestinal adverse effects requiring urgent medical attention if they occur